Budget Impact of Increasing Market Share of Patient Self-Testing and Patient Self-Management in Anticoagulation

Value in Health

Volumn 19, Issue 4, 2016, Pages 383-390

  Stevanović, Jelena ^a   Postma, Maarten J ^a   Le, Hoa H ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

anticoagulation; budget impact analysis; patient self management; patient self testing; point of care devices

Indexed keywords

ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BUDGET IMPACT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; FINANCIAL MANAGEMENT; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MARKETING; NETHERLANDS; PATIENT MONITORING; PATIENT SELF MANAGEMENT; PATIENT SELF TESTING; PRIORITY JOURNAL; RISK FACTOR; SELF CARE; SELF EVALUATION; SENSITIVITY ANALYSIS; THROMBOEMBOLISM; CARDIOVASCULAR DISEASES; COHORT ANALYSIS; COMPLICATION; COST BENEFIT ANALYSIS; ECONOMICS; HEMORRHAGE; MARKOV CHAIN; META ANALYSIS; PROCEDURES; STATISTICS AND NUMERICAL DATA;

ANTICOAGULANTS; CARDIOVASCULAR DISEASES; COHORT STUDIES; COST-BENEFIT ANALYSIS; HEMORRHAGE; HUMANS; MARKOV CHAINS; NETHERLANDS; SELF CARE; THROMBOEMBOLISM;

EID: 84958581085     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2015.12.017     Document Type: Article

References (41)

1. [1] Hirsh, J., Oral anticoagulant drugs. N Engl J Med 324 (1991), 1865–1875.
2. [2] Federatie van Nederlandse Trombosediensten. Samenvatting medische jaarverslagen. 2012. Available from: http://www.fnt.nl/media/docs/jaarverslagen/FNT_Medisch_jaarverslag_2012_WEB.pdf. [Accessed April 9, 2014].
3. [3] Go, A.S., Hylek, E.M., Phillips, K.A., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA 285 (2001), 2370–2375.
4. [4] Colilla, S., Crow, A., Petkun, W., et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the US adult population. Am J Cardiol 112 (2013), 1142–1147.
5. [5] Heeringa, J., van der Kuip, Deirdre, A.M., et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 27 (2006), 949–953.
6. [6] Greenblatt, D.J., Moltke, L.L., Interaction of warfarin with drugs, natural substances, and foods. J Clin Pharmacol 45 (2005), 127–132.
7. [7] Hirsh, J., Dalen, J.E., Anderson, D.R., et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest J 119 (2001), 8S–21S.
8. [8] Fang, M.C., Stafford, R.S., Ruskin, J.N., et al. National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch Intern Med 164 (2004), 55–60.
9. [9] De Schryver, E., Van Gijn, J., Kappelle, L., et al. Non-adherence to aspirin or oral anticoagulants in secondary prevention after ischaemic stroke. J Neurol 252 (2005), 1316–1321.
10. [10] Hylek, E.M., Evans-Molina, C., Shea, C., et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 115 (2007), 2689–2696.
11. [11] Samsa, G.P., Matchar, D.B., Goldstein, L.B., et al. Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med 160 (2000), 967–973.
12. [12] Boulanger, L., Kim, J., Friedman, M., et al. Patterns of use of antithrombotic therapy and quality of anticoagulation among patients with non‐valvular atrial fibrillation in clinical practice. Int J Clin Pract 60 (2006), 258–264.
13. [13] Garcia-Alamino, J.M., Ward, A.M., Alonso-Coello, P., et al. Self-monitoring and self-management of oral anticoagulation. Cochrane Database Syst Rev(4), 2010, CD003839.
14. [14] Heneghan, C., Ward, A., Perera, R., et al. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet 379 (2012), 322–334.
15. [15] Horstkotte, D., Piper, C., Wiemer, M., Optimal frequency of patient monitoring and intensity of oral anticoagulation therapy in valvular heart disease. J Thromb Thrombolysis 5 (1998), 19–24.
16. [16] Connock, M., Stevens, C., Fry-Smith, A., et al. Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling. Health Technol Assess, 11, 2007 iii–iv, ix–66.
17. [17] Mauskopf, J.A., Sullivan, S.D., Annemans, L., et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on Good Research Practices—Budget Impact Analysis. Value Health 10 (2007), 336–347.
18. [18] Sullivan, S.D., Mauskopf, J.A., Augustovski, F., et al. Budget impact analysis—principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health 17 (2014), 5–14.
19. [19] Menéndez-Jándula, B., Souto, J.C., Oliver, A., et al. Comparing self-management of oral anticoagulant therapy with clinic management: a randomized trial. Ann Intern Med 142 (2005), 1–10.
20. [20] Fitzmaurice, D.A., Murray, E.T., McCahon, D., et al. Self management of oral anticoagulation: randomised trial. BMJ, 331, 2005, 1057.
21. [21] Matchar, D.B., Jacobson, A., Dolor, R., et al. Effect of home testing of international normalized ratio on clinical events. N Engl J Med 363 (2010), 1608–1620.
22. [22] Siebenhofer, A., Rakovac, I., Kleespies, C., et al. Self-management of oral anticoagulation reduces major outcomes in the elderly: a randomized controlled trial. Thromb Haemost 100 (2008), 1089–1098.
23. [23] R Development Core Team. R: A Language and Environment for Satistical Computing. 2008, R Foundation for Statistical Computing, Vienna, Austria.
24. [24] Viechtbauer, W., Conducting meta-analyses in R with the metafor package. J Stat Softw 36 (2010), 1–48.
25. [25] Den Haag/Heerlen. Central Institute of Statistics web site. Available from: http://statline.cbs.nl/StatWeb/publication/?DM=SLNL&PA=37530NED&D1=0-1&D2=1-100&D3=0&D4=l&HDR=G1,G2&STB=G3,T&VW=T. [Accessed January 9, 2013].
26. [26] DataMarket. HICP for health for the Netherlands. Available from: http://datamarket.com/data/set/18qu/hicp-2005-100-annual-data-average-index-and-rate-of-change#!ds=18qu!mh6=2:mh7=m:6ggm=s&display=table. [Accessed January 11, 2013].
27. [27] Baeten, S.A., van Exel N, Job A, Dirks, M, et al. Lifetime health effects and medical costs of integrated stroke services—a non-randomized controlled cluster-trial based life table approach. Cost Eff Resour Alloc, 8, 2010, 21.
28. [28] Greving, J, Visseren, F., de Wit, G, et al. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis. BMJ, 342, 2011.
29. [29] Ten Cate‐Hoek, A.J., Toll, D., Büller, H., et al. Cost‐effectiveness of ruling out deep venous thrombosis in primary care versus care as usual. J Thromb Haemost 7 (2009), 2042–2049.
30. [30] Connolly, S.J., Ezekowitz, M.D., Yusuf, S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361 (2009), 1139–1151.
31. [31] Roos, Y.B., Dijkgraaf, M.G., Albrecht, K.W., et al. Direct costs of modern treatment of aneurysmal subarachnoid hemorrhage in the first year after diagnosis. Stroke 33 (2002), 1595–1599.
32. [32] Hakkaart-van Roijen, L., Tan, S., Bouwmans, C., Handleiding voor kostenonderzoek. Methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. Geactualiseerde versie, 2010 (3rd version). Diemen, College voor zorgverzekeringen, 2010.
33. [33] Official Dutch drug prices: Z-index WMG geneesmiddelen, The Hague, 2014 [in Dutch]. Available from: http://www.z-index.nl. [Accessed January 5, 2015].
34. [34] Nederlandse Zorgautoriteit (NZa). Bijlage 1 bij tariefbeschikking TB/CU-7078-01. Available from: http://www.nza.nl/. [Accessed November 18, 2014].
35. [35] Regier, D.A., Sunderji, R., Lynd, L.D., et al. Cost-effectiveness of self-managed versus physician-managed oral anticoagulation therapy. CMAJ 174 (2006), 1847–1852.
36. [36] Lafata, J.E., Martin, S.A., Kaatz, S., et al. Anticoagulation clinics and patient self-testing for patients on chronic warfarin therapy: a cost-effectiveness analysis. J Thromb Thrombolysis 9 (2000), 13–19.
37. [37] Jowett, S., Bryan, S., Murray, E., et al. Patient self‐management of anticoagulation therapy: a trial‐based cost‐effectiveness analysis. Br J Haematol 134 (2006), 632–639.
38. [38] Evans, D., Hierarchy of evidence: a framework for ranking evidence evaluating healthcare interventions. J Clin Nurs 12 (2003), 77–84.
39. [39] Ho, P.M., Peterson, P.N., Masoudi, F.A., Evaluating the evidence: is there a rigid hierarchy?. Circulation 118 (2008), 1675–1684.
40. [40] Nederlandse Vereniging voor Cardiologie. Leidraad begeleide introductie nieuwe orale antistollingsmiddelen. Available from: https://www.nvvc.nl/richtlijnen/bestaande-richtlijnen. [Accessed September 13, 2013].
41. [41] Camm, A.J., Lip, G.Y., De Caterina, R., et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Europace 14 (2012), 1385–1413.